Table 1.
The 10 most cited papers in lung cancer immunotherapy from 2010 to 2022 a .
| Rank | Title | CorrespondingAuthor | Journal | Year | Total citations | Average citations per year (rank) |
|---|---|---|---|---|---|---|
| 1 | Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer | Borghaei H | N Engl J Med | 2015 | 5854 | 878.1 (2) |
| 2 | Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer | Brahmer JR | N Engl J Med | 2016 | 5287 | 946.9 (1) |
| 3 | Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer | Chan TA | Science | 2015 | 4908 | 684.8 (4) |
| 4 | Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer | Brahmer J | N Engl J Med | 2015 | 4612 | 666.8 (5) |
| 5 | Pembrolizumab for the Treatment of Non-Small-Cell Lung Cancer | Garon EB | N Engl J Med | 2015 | 3833 | 541.1 (6) |
| 6 | Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial | Herbst RS | Lancet | 2016 | 3217 | 521.7 (7) |
| 7 | Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer | Gandhi L | N Engl J Med | 2018 | 2827 | 692.3 (3) |
| 8 | Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial | Gandara DR | Lancet | 2017 | 2647 | 488.7 (8) |
| 9 | Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer | Antonia SJ | N Engl J Med | 2017 | 2002 | 436.8 (10) |
| 10 | Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer | Paz-Ares L | N Engl J Med | 2018 | 1568 | 437.6 (9) |
a
These ten papers were all published on N Engl J Med.